ClinicalTrials.gg
CompletedNCT02406248Updated Oct 15, 2018Results posted

Brilinta Taiwan Post Approval Safety Study

A Phase 4 interventional study of Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd) in Non ST-elevation Myocardial Infarction, sponsored by AstraZeneca. Completed at 13 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction

Read the detailed description

This study will be conducted in approximately 8 investigational centres in Taiwan. It is expected that approximately 100 patients will be enrolled into study treatment. This study is to describe the safety and tolerability of ticagrelor, by assessment of the bleeding events and other serious adverse events (SAEs) during 1year follow up in Taiwanese non ST-elevation myocardial infarction (NSTEMI) patients.

02

Conditions studied

  • Non ST-elevation Myocardial Infarction

Keywords

  • NSTEMI
03

In context

Non-ST Elevated Myocardial Infarction

286 studies on the registry are indexed under Non-ST Elevated Myocardial Infarction; 52 are open to participants now.

This study's enrollment of 108 is below the median of 244 across 146 interventional studies indexed under Non-ST Elevated Myocardial Infarction.

Browse Non-ST Elevated Myocardial Infarction studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Female or male aged at least 20 years
  3. Patient who is considered as ethnic Taiwanese
  4. Index event of non-ST elevation myocardial infarction

Exclusion criteria

Exclusion Criteria:

  1. or other reason that ticagrelor should not be administered
  2. Index event is an acute complication of Percutaneous coronary intervention (PCI)
  3. Patient has planned for an urgent coronary artery bypass graft (CABG) within 7 days from the enrolment
  4. Oral anticoagulation therapy within 30 days prior to enrolment or cannot be stopped
  5. Fibrinolytic therapy in the 24 hours prior to enrolment, or planned fibrinolytic treatment following enrolment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    single arm

    Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

    Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

Interventions

  • DrugTicagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

    Drug page: Ticagrelor

    Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

    Also known as: "Brilinta"

06

What researchers measure

Primary outcomes

  1. Number of Participants With Fatal/Life-threatening Bleedings

    Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined fatal/life-threatening bleedings

    Time frame: during 1year follow up with ticagrelor treatment

  2. Number of Participants With Bleeding Events (Major Bleedings)

    Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major bleedings

    Time frame: during 1year follow up with ticagrelor treatment

  3. Number of Participants With Bleeding Events (Major and Minor Bleedings)

    Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major + minor bleedings

    Time frame: during 1year follow up with ticagrelor treatment

  4. Number of Participants With Other Serious Adverse Event (SAEs)

    Evaluation of serious adverse events other than bleedings

    Time frame: during 1year follow up with ticagrelor treatment

  5. Number of Participants With Major Cardiovascular Events

    Evaluation of major cardiovascular events including cardiovascular death, myocardial infarction or stroke

    Time frame: during 1year follow up with ticagrelor treatment

07

Results

Posted Oct 15, 2018

Participant flow

This study was conducted at 13 centres in Taiwan. The first patient was enrolled on 23 April 2015 and the last visit of the last patient took was on 9 February 2017. Informed consent was received for 113 patients

Participant flow — Overall Study
MilestoneSingle Arm
Started108
Completed99
Not completed9
Withdrew: Death7
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Participants With Fatal/Life-threatening Bleedings

Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined fatal/life-threatening bleedings

Time frame:
during 1year follow up with ticagrelor treatment
Reported as:
Count of participants · Participants
Number of Participants With Fatal/Life-threatening Bleedings
ParticipantsSingle Arm
Fatal/life-threatening bledings4
PrimaryNumber of Participants With Bleeding Events (Major Bleedings)

Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major bleedings

Time frame:
during 1year follow up with ticagrelor treatment
Reported as:
Count of participants · Participants
Number of Participants With Bleeding Events (Major Bleedings)
ParticipantsSingle Arm
Major bleedings7
PrimaryNumber of Participants With Bleeding Events (Major and Minor Bleedings)

Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major + minor bleedings

Time frame:
during 1year follow up with ticagrelor treatment
Reported as:
Count of participants · Participants
Number of Participants With Bleeding Events (Major and Minor Bleedings)
ParticipantsSingle Arm
Major and minor bleedings20
PrimaryNumber of Participants With Other Serious Adverse Event (SAEs)

Evaluation of serious adverse events other than bleedings

Time frame:
during 1year follow up with ticagrelor treatment
Reported as:
Count of participants · Participants
Number of Participants With Other Serious Adverse Event (SAEs)
ParticipantsSingle Arm
Serious adverse events other than bleeding21
PrimaryNumber of Participants With Major Cardiovascular Events

Evaluation of major cardiovascular events including cardiovascular death, myocardial infarction or stroke

Time frame:
during 1year follow up with ticagrelor treatment
Reported as:
Count of participants · Participants
Number of Participants With Major Cardiovascular Events
ParticipantsSingle Arm
Composite of major cardiovascular events6

Adverse events

Collected over On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. 1year if the participant completed treatment according to the study plan. All-cause mortality is collected during 1 year follow-up, including deaths that occur more than 7 days after last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm7/108 (6.5%)23/108 (21.3%)45/108 (41.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventSingle Arm
PneumoniaInfections and infestations4/108
Angina pectorisCardiac disorders2/108
SepsisInfections and infestations1/108
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/108
Haemorrhagic transformation strokeNervous system disorders1/108
GlaucomaEye disorders1/108
VertigoEar and labyrinth disorders1/108
Acute coronary syndromeCardiac disorders1/108
Acute myocardial infarctionCardiac disorders1/108
Cardiogenic shockCardiac disorders1/108
Most frequent other events
Most frequent other events
EventSingle Arm
CoughRespiratory, thoracic and mediastinal disorders10/108
DyspnoeaRespiratory, thoracic and mediastinal disorders10/108
EcchymosisSkin and subcutaneous tissue disorders10/108
HypokalaemiaMetabolism and nutrition disorders8/108
ContusionInjury, poisoning and procedural complications7/108
Angina pectorisCardiac disorders6/108
DiarrhoeaGastrointestinal disorders6/108
HyperuricaemiaMetabolism and nutrition disorders6/108
PyrexiaGeneral disorders6/108
Urinary tract infectionInfections and infestations6/108

Baseline characteristics

Age, Continuous
Age, Continuous(years)Single Arm
Mean61.7 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female22
Male86
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single Arm
Asian108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single Arm
Not hispanic or latino108
08

Study locations

13 sites
  • Research Site
    Changhua City, 50006, Taiwan
  • Research Site
    Hsinchu, 300, Taiwan
  • Research Site
    Kaohsiung, 80756, Taiwan
  • Research Site
    Kaohsiung, 81362, Taiwan
  • Research Site
    Niao-Song-Shiang, 833, Taiwan
  • Research Site
    Taichung, Taiwan
  • Research Site
    Tainan County, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 104, Taiwan
  • Research Site
    Taipei, 11101, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taipei, 11220, Taiwan
  • Research Site
    Taipei, 22060, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Feb 2017, 21 months.

Results were first posted in Oct 2018, 1 year 8 months after primary completion.

Of 23 phase 4 interventional studies under Non-ST Elevated Myocardial Infarction, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 74. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2015
First posted
Apr 2, 2015
StartActual
Apr 23, 2015
Primary completionActual
Feb 9, 2017
CompletionActual
Feb 9, 2017
Results first posted
Oct 15, 2018
Last update
Oct 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02406248
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 2, 2015
Start date
Apr 23, 2015
Primary completion
Feb 9, 2017
Completion
Feb 9, 2017
Results posted
Oct 15, 2018
Last update
Oct 15, 2018

Study contacts

Chun-peng Liu, Ph.D
principal investigator · Kaohsiung Veterans General Hospital.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion